Kevin P. Daly, MD
Medical Director, Heart Transplant Program; Associate Cardiologist, Department of Cardiology
Assistant Professor of Pediatrics, Harvard Medical School
Image
Kevin P. Daly, MD
Medical Director, Heart Transplant Program; Associate Cardiologist, Department of Cardiology
Assistant Professor of Pediatrics, Harvard Medical School
Medical Services
Languages
English
Education
Undergraduate School
Biochemical Sciences
Harvard University
2000
Boston
MA
Medical School
Columbia University College of Physicians & Surgeons
2004
New York
NY
Internship
Children’s Hospital at Montefiore
2005
Bronx
NY
Residency
Pediatrics
Children’s Hospital at Montefiore
2007
Bronx
NY
Fellowship
Pediatric Cardiology
Boston Children's Hospital
2009
Boston
MA
Fellowship
Chief Fellow, Pediatric Cardiology
Boston Children's Hospital
2010
Boston
MA
Fellowship
Pediatric Cardiology; Heart Failure; Transplantation Senior Fellow
Boston Children's Hospital
2011
Boston
MA
Certifications
American Board of Pediatrics (General)
American Board of Pediatrics (Cardiology)
Professional History
I am a pediatric cardiologist at Boston Children’s Hospital specializing in Heart Failure & Transplantation. My clinical work is focused on the evaluation and management of children with advanced heart failure and those requiring mechanical circulatory support and/or heart transplantation. I am also a translational researcher focused on the development of biomarkers and novel imaging technologies which will allow for non-invasive diagnosis of cardiac allograft vasculopathy (CAV).
I am a clinical expert in the diagnosis and management of the highly sensitized pediatric heart transplant patient and those who develop antibody mediated rejection. I have published our center’s experience with peri-operative desensitization for crossmatch positive heart transplantation and utilized eculizumab (a terminal complement inhibitor) and bortezomib (a proteasome inhibitor) for the treatment of antibody mediated rejection. I am the only transplant physician in our group to perform intracardiac hemodynamics, endomyocardial biopsies, and coronary angiography in transplant patients and have expertise in the diagnosis of CAV.
I have demonstrated that VEGF-A can be used to stratify risk for development CAV in children after heart transplantation. We are planning a prospective study to determine if VEGF-A testing can safely reduce the frequency of invasive coronary angiography procedures in pediatric heart transplant recipients. In addition, I am leading a multi-center collaboration to design and perform the first randomized control trial of maintenance immunosuppression in pediatric heart transplantation. We expect this trial will support the first FDA approved indication for maintenance immunosuppression in pediatric heart transplantation.
Approach to Care
Having a sick child can leave parents feeling scared and powerless. My goal is to help children and parents understand their illness so that they can regain some amount of control. Educating children, families, and other medical providers about heart failure is a key component of that process. We can then discuss treatment options and make the best decision for each individual child and family.
Medicine is a calling. I became a doctor because I wanted to be able to help, protect and heal. Since I was a child, I been fascinated with how things work and how we can make them work better. Medicine challenges me to understand how to modify complex diseases processes with a goal of improving patient outcomes and quality of life.
Medicine is a calling. I became a doctor because I wanted to be able to help, protect and heal. Since I was a child, I been fascinated with how things work and how we can make them work better. Medicine challenges me to understand how to modify complex diseases processes with a goal of improving patient outcomes and quality of life.
Publications
Everolimus and Low-Dose Tacrolimus After Heart Transplant in Children: A Randomized Clinical Trial. View Abstract
Partial Heart Transplants-Growing Data for Growing Valves. View Abstract
Addressing vaccination coverage among pediatric solid organ transplant candidates and recipients in the post-COVID-19 pandemic period of increased vaccine hesitancy. View Abstract
Daratumumab for Anti-HLA Antibody Desensitization and Antibody Mediated Rejection in Pediatric Heart Transplant Patients. View Abstract
Management of acute cellular rejection after pediatric heart transplantation. View Abstract
Postoperative Dialysis in Fontan Patients Undergoing Heart Transplant: How Predictive is the Pretransplant Serum Creatinine? View Abstract
Socioeconomic Status and Major Adverse Transplant Events in Pediatric Heart Transplant Recipients. View Abstract
Sacubitril/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial. View Abstract
International Society for Heart and Lung Transplantation Guidelines for the Evaluation and Care of Cardiac Transplant Candidates-2024. View Abstract
Improving Mechanical Circulatory Support Outcomes in Failing Bidirectional Glenn Physiology. View Abstract
Pathology of explanted pediatric hearts: An 11-year study. Population characteristics and implications for outcomes. View Abstract
Impact of a positive crossmatch on pediatric heart transplant outcomes. View Abstract
Detecting and managing cardiac allograft vasculopathy within the transition from pediatric to adult heart transplantation care: Lighting the pathway ahead. View Abstract
Medium-term Outcomes in Pediatric Heart Transplant Recipients Managed Using a Steroid Avoidance Immune Suppression Protocol. View Abstract
Survivors of Pediatric Hematopoietic Stem Cell Transplantation Exhibit Progressive Diastolic Dysfunction Over Years of Follow-Up. View Abstract
ABO-Incompatible Heart Transplantation: Where Science, Society, and Policy Collide. View Abstract
External assessment and refinement of a population pharmacokinetic model to guide tacrolimus dosing in pediatric heart transplant. View Abstract
Fecal Microbiota Transplant in Pediatric Solid Organ Transplant Recipients. View Abstract
The teammate trial: Study design and rationale tacrolimus and everolimus against tacrolimus and MMF in pediatric heart transplantation using the major adverse transplant event (MATE) score. View Abstract
Apixaban Anticoagulation in Children and Young Adults Supported With the HeartMate 3 Ventricular Assist Device. View Abstract
Equity factors in pediatric transplant listing: Initial findings from a single center review. View Abstract
The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. View Abstract
Prognostic Value of Exercise Stress Echocardiography in Pediatric Cardiac Transplant Recipients. View Abstract
The Burden of Pediatric Heart Failure That Lies Just Under the Surface. View Abstract
Experience with live attenuated varicella vaccination in pediatric heart transplant recipients: Considering a new path forward. View Abstract
Waitlist Outcomes for Children With Congenital Heart Disease: Lessons Learned From Over 5000 Heart Transplant Listings in the United States. View Abstract
Pediatric heart transplant waiting times in the United States since the 2016 allocation policy change. View Abstract
Giant Cell Myocarditis and Left Ventricular Apical Aneurysm in a Child With Severe Combined Immunodeficiency. View Abstract
Giant Cell Myocarditis in Children: Elusive Giant Cells Might Not Be the Only Clue. View Abstract
Clinical and hemodynamic characteristics of the pediatric failing Fontan. View Abstract
ISHLT consensus statement for the selection and management of pediatric and congenital heart disease patients on ventricular assist devices Endorsed by the American Heart Association. View Abstract
Assessment and Treatment of a Young Adult with Congenital Heart Disease and ADHD. View Abstract
Hepatorenal dysfunction assessment with the Model for End-Stage Liver Disease Excluding INR score predicts worse survival after heart transplant in pediatric Fontan patients. View Abstract
Retrospective Analysis of Clinical Genetic Testing in Pediatric Primary Dilated Cardiomyopathy: Testing Outcomes and the Effects of Variant Reclassification. View Abstract
The ABO-incompatible paradigm shifts only as far as allocation policy allows. View Abstract
Brighter Future for Children with Congenital Heart Disease Requiring Heart Transplantation? A UNOS Registry Analysis over the Last Three Decades. View Abstract
The TEAMMATE Trial: Study Design and Rationale of the First Pediatric Heart Transplant Randomized Clinical Trial. View Abstract
Coagulation Monitoring Correlation with Bivalirudin Dosing in Pediatric Ventricular Assist Device Support. View Abstract
Marijuana in pediatric and adult congenital heart disease heart transplant listing: A survey of provider practices and attitudes. View Abstract
Association of Clinical Rejection Versus Rejection on Protocol Biopsy With Cardiac Allograft Vasculopathy in Pediatric Heart Transplant Recipients. View Abstract
Use of the terminal complement inhibitor eculizumab in paediatric heart transplant recipients. View Abstract
Current evaluation and management of plastic bronchitis in the pediatric population. View Abstract
Myocardial Infarct After Marijuana Inhalation in a 16-year-old Adolescent Boy. View Abstract
Heart failure after the Norwood procedure: An analysis of the Single Ventricle Reconstruction Trial. View Abstract
Managing risk of surgical procedures in pediatric transplant recipients taking mTOR inhibitors: What is the optimal strategy? View Abstract
Clinical practice patterns are relatively uniform between pediatric heart transplant centers: A survey-based assessment. View Abstract
The Evolution of a Pediatric Ventricular Assist Device Program: The Boston Children's Hospital Experience. View Abstract
Development and validation of a major adverse transplant event (MATE) score to predict late graft loss in pediatric heart transplantation. View Abstract
Into the hearts of babes: Stem cell therapy for pediatric heart failure. View Abstract
Dilated Cardiomyopathy in a 2-Year-Old Infant. View Abstract
Vascular endothelial growth factor A is associated with the subsequent development of moderate or severe cardiac allograft vasculopathy in pediatric heart transplant recipients. View Abstract
Cholesterol efflux capacity of high-density lipoprotein correlates with survival and allograft vasculopathy in cardiac transplant recipients. View Abstract
Is Endomyocardial Biopsy a Safe and Useful Procedure in Children with Suspected Cardiomyopathy? View Abstract
Finding the correct role for heart transplant in the treatment of hypoplastic left heart syndrome. View Abstract
What Is the Role of Developmental Disability in Patient Selection for Pediatric Solid Organ Transplantation? View Abstract
Use of [18F]FDG Positron Emission Tomography to Monitor the Development of Cardiac Allograft Rejection. View Abstract
Multicenter Analysis of Immune Biomarkers and Heart Transplant Outcomes: Results of the Clinical Trials in Organ Transplantation-05 Study. View Abstract
Summary of the 2015 International Paediatric Heart Failure Summit of Johns Hopkins All Children's Heart Institute. View Abstract
Emerging science in paediatric heart transplantation: donor allocation, biomarkers, and the quest for evidence-based medicine. View Abstract
Translational implications of endothelial cell dysfunction in association with chronic allograft rejection. View Abstract
Circulating donor-derived cell-free DNA: a true biomarker for cardiac allograft rejection? View Abstract
Antibody depletion for the treatment of crossmatch-positive pediatric heart transplant recipients. View Abstract
Effect of inhaled iloprost on the exercise function of Fontan patients: a demonstration of concept. View Abstract
VEGF-C, VEGF-A and related angiogenesis factors as biomarkers of allograft vasculopathy in cardiac transplant recipients. View Abstract
Key Features of the Intragraft Microenvironment that Determine Long-Term Survival Following Transplantation. View Abstract
Endomyocardial biopsy and selective coronary angiography are low-risk procedures in pediatric heart transplant recipients: results of a multicenter experience. View Abstract
Sudden death after pediatric heart transplantation: analysis of data from the Pediatric Heart Transplant Study Group. View Abstract
Changes in echocardiographic measures of systolic and diastolic function in children 1 year after hematopoietic SCT. View Abstract
Variant translocation with a deletion of derivative (9q) in a case of Philadelphia chromosome positive (Ph +) essential thrombocythemia (ET), a variant of chronic myelogenous leukemia (CML) with a poor prognosis. View Abstract
Locations